Guest guest Posted September 26, 2008 Report Share Posted September 26, 2008 Hormone refractory prostate cancer (HRCP) is rising with the increasing incidence of prostate cancer coupled with a prognosis of greater life expectancy,and could soon represent the most common cancer in the male population. The clinical variability, the lack of consensus on patients' eligibility for starting a different treatment, and the response criteria seen in literature have made it difficult to evaluate the impact of treatments. Click on the below link for the full story:<http://www.medicalnewstoday.com/articles/123206.php> Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.